For a transplant-eligible myelofibrosis patient with a large spleen, using an upfront combination therapy is a compelling strategy. Reducing spleen size pre-transplant is known to improve engraftment, making this a clear clinical scenario for more aggressive initial treatment to optimize outcomes.

A proactive clinical practice is to refer all newly diagnosed myelofibrosis patients for a transplant consultation, irrespective of their initial risk score. This preemptive step helps overcome significant logistical delays in finding a suitable donor, which is particularly crucial for patients from diverse ethnic backgrounds where donor availability is limited.

For myelofibrosis patients with profound splenomegaly but only moderate thrombocytopenia (platelets 50k-100k), fedratinib may be the best frontline option. It is arguably the most potent JAK inhibitor for spleen reduction and is approved for use in patients with platelet counts as low as 50,000.

Interferon therapy is being evaluated in a distinct niche from JAK inhibitors. It is targeted at patients with early or low-risk myelofibrosis, not for immediate symptom control, but with the strategic goal of potentially modifying the disease course and slowing its natural progression.

When treating frail, elderly myelofibrosis patients with ruxolitinib, the focus should be on the speed of dose escalation. While starting low is common, clinicians must titrate up every few weeks, not months, to reach the target therapeutic level and avoid undertreatment.

A critical challenge in myelofibrosis care is that the optimal time for a curative transplant is when patients feel well, often due to effective JAK inhibitor therapy. This feeling of well-being makes them reluctant to undergo the high-risk procedure. Waiting until they feel sick makes the transplant less likely to succeed.

A patient's risk score primarily determines their candidacy for a stem cell transplant. However, the decision to start a JAK inhibitor is driven by symptoms like splenomegaly and constitutional issues, regardless of the patient's formal risk status. This decouples two key treatment decisions.

For myelofibrosis patients with both anemia and splenomegaly, a practical approach is to start with ruxolitinib for its superior symptom control. If the subsequent anemia is not well-tolerated, switching to momelotinib allows for a more informed, personalized decision based on the patient's experience with both agents.

Clinicians should interpret anemia in myelofibrosis patients on JAK inhibitors based on its timing. Anemia in the first 16 weeks is an expected on-target effect. In contrast, new anemia in a patient on a stable dose is a warning sign that may indicate disease progression, warranting further investigation.